NCT00002253已完成不适用
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Sandoz
- 试验地点
- 22
研究概览
简要总结
The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA 102A).
The secondary objectives include: 1) To evaluate clinical efficacy and safety of open-label Sandostatin in patients who were "Non-Responders" in Study #D203 - FDA 102A; 2) To evaluate the efficacy and safety of Sandostatin during prolonged open-label treatment in "Responders" from Study #D03 - FDA 102A.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the following:
- •Only patients who have completed the duration of Study D203, FDA 102A will be eligible for this study.
- •Each of these patients must give written informed consent to participate in Study D204, FDA 102B as well.
排除标准
- 未提供
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)Purpura, Thrombocytopaenic, IdiopathicNCT00102739GlaxoSmithKline99
Unknown
不适用
The Auxiliary Effects of Fucoidan for Locally Advanced Rectal Cancer PatientsTo Observe Whether the Fucoidan Can Improve the Quality of Life of the Such Patients Receiving the Neoadjuvant CCRTNCT04342949Kaohsiung Medical University Chung-Ho Memorial Hospital100
撤回
2 期
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's DiseaseCrohn's DiseaseNCT01635621UCB BIOSCIENCES GmbH
已完成
2 期
Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT01694485Amgen359
终止
2 期
A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic SclerosisSclerosis, SystemicDiffuse Cutaneous Systemic SclerosisNCT04781543Amgen301